LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Stock List・Arvinas Inc

Arvinas Inc

Closed

SectorHealthcare

7.69 0.13

Buy Sell

Overview

Share price change

24h

Current

Min

7.6899999999999995

Max

7.89

Key metrics
By Trading Economics
Income	9.8M -58M
Sales	6.1M 16M
EPS	-0.9
Profit margin	-369.231
Employees	246
EBITDA	4.4M -62M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+90.78% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-70M 554M
Previous open	7.56
Previous close	7.69

News Sentiment

By Acuity

33%

67%

84 / 344 Healthcare

Arvinas Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jun 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 Jun 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 Jun 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 Jun 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 Jun 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 Jun 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Jun 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 Jun 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 Jun 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 Jun 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 Jun 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 Jun 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 Jun 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 Jun 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 Jun 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 Jun 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 Jun 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 Jun 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 Jun 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 Jun 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 Jun 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 Jun 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 Jun 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 Jun 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 Jun 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Arvinas Inc Forecast

Price Target

By TipRanks

90.78% upside

12 Months Forecast

Average 14.69 USD 90.78%

High 24 USD

Low 6 USD

Based on 14 Wall Street analysts offering 12 month price targets forArvinas Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Arvinas Inc - Dist in the past 3 months.

Sentiment

By Acuity

84 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.